Gyre Therapeutics (NASDAQ: GYRE) — Perfil da empresa, notícias e dados financeiros
Gyre Therapeutics innovates drug therapies to address unmet medical needs, focusing on improving patient outcomes through advanced research.
Gyre Therapeutics
Gyre Therapeutics (NASDAQ:GYRE) is dedicated to advancing healthcare through innovation in drug therapies, focusing its efforts on addressing unmet medical needs across a variety of conditions. While the company leans heavily on cutting-edge research and development to fuel its pipeline of novel treatments, it prides itself on a multidisciplinary approach that combines biological insights with advanced technology to develop safer, more effective medications. Gyre Therapeutics’ projects span from early-stage research to late-stage clinical trials, emphasizing collaboration with healthcare professionals and patients to ensure its objectives align with real-world demands. The company aims to significantly improve patient outcomes through its therapeutic advancements, showcasing a commitment to enhancing the quality of life for individuals around the globe.
Resumo
Operações
Produtos e/ou serviços de Gyre Therapeutics
- Development of innovative gene therapies targeting chronic and age-related diseases.
- Creation of proprietary platforms for the delivery of genetic material into cells.
- Research into novel methods for managing and treating neurodegenerative disorders.
- Engagement in collaborations with academia and industry to enhance gene therapy techniques.
- Production of scalable and efficient gene editing tools for clinical use.
- Provision of consulting services on genetic therapy strategies and regulatory pathways.
equipe executiva do Gyre Therapeutics
- Thomas W. EastlingChief Financial Officer
- Weiguo YeChief Operating Officer
- Ruoyu ChenChief Information Officer
- Ying LuoCEO, President & Director
- Yue XiongChief Scientific Officer & Director
- Joshua BergmannGeneral Counsel & Corporate Secretary
- Seth GoldblumSenior Vice President of Corporate Development
- Jialiang WangExecutive VP & GM
- Jing LiuSenior Vice President of Platform Chemistry
- Mark MarinoSenior Vice President of Clinical Development
Histórico de dividendos
Dividendos por ação pagos pela Gyre Therapeutics, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2023 | — | — | — | $3.6000 |
| FY2022 | — | — | — | $21.4500 |
| FY2015 | — | — | — | $896.1750 |
Principais indicadores financeiros
Resultados divulgados pela Gyre Therapeutics, em USD.
- Cap. de mercado
- 751,8 mi
- Receita (TTM)
- 109,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- -19.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 116,6 mi | 11,5 mi | 5 mi | |
| 105,8 mi | 16,2 mi | 12,1 mi | |
| 113,5 mi | -67,2 mi | -92,9 mi | |
| 102,3 mi | 9,2 mi | 2,3 mi |